BioCentury on BioBusiness,
Product Discovery & Development
Efficacy, MOA behind Opexa's shift to secondary progressive MS for Tcelna
Opexa's progression in MS
By Erin McCallister
Senior Writer
Published on
Monday, October 8, 2012
Two years after Tcelna failed a Phase II trial in
relapsing-remitting multiple sclerosis, Opexa
Therapeutics Inc. has restarted development of the cell therapy with a
new focus on secondary progressive MS. The company is going after later stage,
active disease because the cell therapy's mode of action suggests it is more
effective in that setting.
The autologous cell therapy
contains myelin reactive T cells (MRTCs) primed and expanded ex vivo with
myelin basic protein (MBP), proteolipid protein 1 (PLP1) and myelin
oligodendrocyte glycoprotein (MOG). These proteins are expressed on the surface
of MRTCs - the cells that destroy the myelin sheath in MS patients.
104
words displayed of
1157
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]